Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

Sacchi, Stefano; Federico, Massimo; Dastoli, Giuseppe; Fiorani, Claudia; Vinci, G; Clò, Vera; Casolari, Barbara

doi:10.1016/s1040-8428(00)00069-x

Cited by 35 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specific immunotherapies including cancer vaccines and monoclonal antibodies may be complementary alternatives. Monoclonal antibodies have been shown to induce tumor regression (2,3) and survival benefits in adjuvant settings in patients with CRC (4,5).…”

Section: Introductionmentioning

confidence: 99%

Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor

Ullenhag

Frödin

Jeddi-Tehrani

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor

Ullenhag

Frödin

Jeddi-Tehrani

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The most widely studied examples of differentiation antigens currently being used for targeted therapy are expressed by hematopoietic malignancies, and include CD-20, CD-22 and CD-30 on B-cell lymphomas CD-33, CD-38, CD-45 and CD-64 on acute myeloid leukemias (AML) and the upregulated interleukin (IL-)-2 receptor on T-cell leukemias (Favaloro et al, 1987;Waldmann et al, 1992;Sacchi et al, 2001;Waldmann, 2002;Tur et al, 2003;Leonard et al, 2004;Matthey et al, 2004;Mehta et al, 2004;Sperr et al, 2005).…”

Section: Differentiation Antigensmentioning

confidence: 99%

Novel antibodies as anticancer agents

2007

View full text Add to dashboard Cite

In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.

show abstract

“…It is a human IgGl kappa antibody with mouse variable regions isolated from a murine anti-CD20 antibody, IDEC-2B8, that binds with high affinity to cells expressing the CD20 antigen found on the surface of malignant and normal B cells, but not on other normal tissues. It mediates complement-dependent cell lyses in the presence of human complement, and antibody-dependent cellular cytotoxicity with human effector cells [21]. The Food and Drug Administration (FDA) approved rituximab in 1997 and the European Union (EU) in 1998 for the treatment of relapsed or refractory, CD20-positive, B-cell, low-grade or follicular nonHodgkin's lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

Garcı́a¹,

Bonamigo-Filho²,

Neumann³

et al. 2003

Transplant Int

View full text Add to dashboard Cite

Post-transplant lymphoproliferative disease (PTLD) is an uncommon but life-threatening complication of solid-organ and blood stem-cell transplants. It responds poorly to therapy, including reduction of immunosuppression, interferon, antivirals or chemotherapy. Small series of PTLD successfully treated with rituximab have been reported, and experimental studies suggest that rapamycin inhibits growth of human Epstein-Barr virus-transformed B lymphocytes. We report two cases of PTLD after renal transplantation that were successfully treated with rituximab in association with rapamycin. This report suggests that rituximab associated with rapamycin could be an effective and safe treatment for PTLD.

show abstract

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

Cited by 35 publications

References 27 publications

Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor

Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor

Novel antibodies as anticancer agents

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

Contact Info

Product

Resources

About